Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations

New England Journal of Medicine

Volumn 355, Issue 5, 2006, Pages 467-477

  Pearson, Ewan R ^a,b   Flechtner, Isabelle ^f   Njølstad, Pål R ^g,h   Malecki, Maciej T ⁱ   Flanagan, Sarah E ^a   Larkin, Brian ^c   Ashcroft, Frances M ^c   Klimes, Iwar ^j   Codner, Ethel ^k   Iotova, Violeta ^l   Slingerland, Annabelle S ^a,m   Shield, Julian ^d   Robert, Jean Jacques ^f   Holst, Jens J ⁿ   Clark, Penny M ^e   Ellard, Sian ^a   Søvik, Oddmund ^g   Polak, Michel ^f   Hattersley, Andrew T ^a  

^a PENINSULA MEDICAL SCHOOL   (United Kingdom)

^b UNIVERSITY OF DUNDEE   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d UNIVERSITY OF BRISTOL   (United Kingdom)

^e UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

^f UNIVERSITÉ PARIS DESCARTES   (France)

^g UNIVERSITY OF BERGEN   (Norway)

^h HAUKELAND UNIVERSITY HOSPITAL   (Norway)

ⁱ JAGIELLONIAN UNIVERSITY   (Poland)

^j INSTITUTE OF EXPERIMENTAL ENDOCRINOLOGY   (Slovakia)

^k UNIVERSITY OF CHILE   (Chile)

^l MEDICAL UNIVERSITY OF VARNA   (Bulgaria)

^m LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

ⁿ UNIVERSITY OF COPENHAGEN   (Denmark)

more..

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; INSULIN; INWARDLY RECTIFYING POTASSIUM CHANNEL SUBUNIT KIR6.2; TOLBUTAMIDE;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DEMOGRAPHY; DIABETES MELLITUS; DIARRHEA; DIET SUPPLEMENTATION; DRUG EFFECT; FEMALE; HUMAN; INSULIN RELEASE; MALE; MUTATION; NEWBORN; OOCYTE; PRIORITY JOURNAL; XENOPUS;

ATP-BINDING CASSETTE TRANSPORTERS; COHORT STUDIES; DIABETES MELLITUS; FEMALE; GLYBURIDE; HEMOGLOBIN A, GLYCOSYLATED; HETEROZYGOTE; HUMANS; HYPOGLYCEMIC AGENTS; INFANT; INFANT, NEWBORN; INSULIN; INSULIN-SECRETING CELLS; MALE; MUTATION; POTASSIUM CHANNELS; POTASSIUM CHANNELS, INWARDLY RECTIFYING; RECEPTORS, DRUG; SULFONYLUREA COMPOUNDS; TOLBUTAMIDE;

EID: 33746686369     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa061759     Document Type: Article

References (30)

1. Gloyn AL, Pearson ER, Antcliff JF, et al. Activating mutations in the gene encoding the ATP-sensitive potassium-channel subunit Kir6.2 and permanent neonatal diabetes. N Engl J Med 2004;350:1838-49. [Erratum, N Engl J Med 2004;351:1470.]
2. Sagen JV, Raeder H, Hathout E, et al. Permanent neonatal diabetes due to mutations in KCNJ11 encoding Kir6.2: patient characteristics and initial response to sulfonylurea therapy. Diabetes 2004;53:2713-8.
3. Vaxillaire M, Populaire C, Busiah K, et al. Kir6.2 mutations are a common cause of permanent neonatal diabetes in a large cohort of French patients. Diabetes 2004;53:2719-22.
4. Zung A, Glaser B, Nimri R, Zadik Z. Glibenclamide treatment in permanent neonatal diabetes mellitus due to an activating mutation in Kir6.2. J Clin Endocrinol Metab 2004;89:5504-7.
5. Massa O, Iafusco D, D'Amato E, et al. KCNJ11 activating mutations in Italian patients with permanent neonatal diabetes. Hum Mutat 2005;25:22-7.
6. Hattersley AT, Ashcroft FM. Activating mutations in Kir6.2 and neonatal diabetes: new clinical syndromes, new scientific insights, and new therapy. Diabetes 2005;54:2503-13.
7. Flanagan SE, Edghill EL, Gloyn AL, Ellard S, Hattersley AT. Mutations in KCNJ11, which encodes Kir6.2, are a common cause of diabetes diagnosed in the first 6 months of life, with the phenotype determined by genotype. Diabetologia 2006;49:1190-7.
8. Gloyn AL, Reimann F, Girard C, et al. Relapsing diabetes can result from moderately activating mutations in KCNJ11. Hum Mol Genet 2005;14:925-34.
9. Gloyn AL, Cummings EA, Edghill EL, et al. Permanent neonatal diabetes due to paternal germline mosaicism for an activating mutation of the KCNJ11 gene encoding the Kir6.2 subunit of the beta-cell potassium adenosine triphosphate channel. J Clin Endocrinol Metab 2004;89:3932-5.
10. Proks P, Antcliff JF, Lippiat J, Gloyn AL, Hattersley AT, Ashcroft FM. Molecular basis of Kir6.2 mutations associated with neonatal diabetes or neonatal diabetes plus neurological features. Proc Natl Acad Sci U S A 2004;101:17539-44.
11. Proks P, Girard C, Haider S, et al. A gating mutation at the internal mouth of the Kir6.2 pore is associated with DEND syndrome. EMBO Rep 2005;6:470-5.
12. Codner E, Flanagan S, Ellard S, Garcia H, Hattersley AT. High-dose glibenclamide can replace insulin therapy despite transitory diarrhea in early-onset diabetes caused by a novel R201L Kir6.2 mutation. Diabetes Care 2005;28:758-9.
13. Klupa T, Edghill EL, Nazim J, et al. The identification of a R201H mutation in KCNJ11, which encodes Kir6.2, and successful transfer to sustained-release sulphonylurea therapy in a subject with neonatal diabetes: evidence for heterogeneity of beta cell function among carriers of the R201H mutation. Diabetologia 2005;48:1029-31.
14. Rohlfing CL, Wiedmeyer HM, Little RR, England JD, Tennill A, Goldstein DE. Defining the relationship between plasma glucose and HbA(1c): analysis of glucose profiles and HbA(1c) in the Diabetes Control and Complications Trial. Diabetes Care 2002;25:275-8.
15. Krarup T, Madsbad S, Moody AJ, et al. Diminished immunoreactive gastric inhibitory polypeptide response to a meal in newly diagnosed type I (insulin-dependent) diabetics. J Clin Endocrinol Metab 1983;56:1306-12.
16. Holst JJ. Evidence that enteroglucagon (II) is identical with the C-terminal sequence (residues 33-69) of glicentin. Biochem J 1982;207:381-8.
17. Orskov C, Rabenhoj L, Wettergren A, Kofod H, Holst JJ. Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide I in humans. Diabetes 1994;43:535-9.
18. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-86.
19. Nauck MA, El-Ouaghlidi A, Gabrys B, et al. Secretion of incretin hormones (GIP and GLP-1) and incretin effect after oral glucose in first-degree relatives of patients with type 2 diabetes. Regul Pept 2004;122:209-17.
20. Muscelli E, Mari A, Natali A, et al. Impact of incretin hormones on {beta}-cell function in subjects with normal or impaired glucose tolerance. Am J Physiol Endocrinol Metab (in press).
21. Koster JC, Remedi MS, Dao C, Nichols CG. ATP and sulfonylurea sensitivity of mutant ATP-sensitive K+ channels in neonatal diabetes: implications for pharmacogenomic therapy. Diabetes 2005;54:2645-54.
22. Sagen JV, Pearson ER, Johansen A, et al. Preserved insulin response to tolbutamide in hepatocyte nuclear factor-1alpha mutation carriers. Diabet Med 2005;22:406-9.
23. Kennedy HJ, Pouli AE, Ainscow EK, Jouaville LS, Rizzuto R, Rutter GA. Glucose generates sub-plasma membrane ATP microdomains in single islet beta-cells: potential role for strategically located mitochondria. J Biol Chem 1999;274:13281-91.
24. Maechler P, Wang H, Wollheim CB. Continuous monitoring of ATP levels in living insulin secreting cells expressing cytosolic firef ly luciferase. FEBS Lett 1998;422:328-32.
25. Freeman H, Shimomura K, Horner E, Cox RD, Ashcroft FM. Nicotinamide nucleotide transhydrogenase: a key role in insulin secretion. Cell Metab 2006;3:35-45.
26. Ashcroft F, Rorsman P. Type 2 diabetes mellitus: not quite exciting enough? Hum Mol Genet 2004;13:Spec No. 1:R21-R31.
27. Proks P, Arnold AL, Bruining J, et al. A heterozygous activating mutation in the sulphonylurea receptor SUR1 (ABCC8) causes neonatal diabetes. Hum Mol Genet 2006;15:1793-800.
28. Babenko AP, Polak M, Cavé H, et al. Activating mutations in the ABCC8 gene in neonatal diabetes mellitus. N Engl J Med 2006;355:456-66.
29. Slingerland AS, Hattersley AT. Mutations in the Kir6.2 subunit of the KATP channel and permanent neonatal diabetes: new insights and new treatment. Ann Med 2005;37:186-95.
30. Stoffers DA, Zinkin NT, Stanojevic V, Clarke WL, Habener JF. Pancreatic agenesis attributable to a single nucleotide deletion in the human IPF1 gene coding sequence. Nat Genet 1997;15:106-10.